A major Boxed Warning has been added to the label for Metformin Hydrochloride, effective 2026-06-25. This warning addresses the serious risk of lactic acidosis. Postmarketing cases of metformin-associated lactic acidosis have resulted in death, hypothermia, hypotension, and resistant bradyarrhythmias. The onset of metformin-associated lactic acidosis is often.
Background
Metformin Hydrochloride is a medication, often found as a component in combination products. For instance, it is combined with canagliflozin in drugs like Invokamet XR. Other related drugs mentioned include dapagliflozin and empagliflozin. The new Boxed Warning specifically pertains to the metformin component of these medications.
What this means
The addition of a major Boxed Warning to the Metformin Hydrochloride label signifies a critical safety update for healthcare providers and patients. This warning highlights the severe and potentially fatal nature of metformin-associated lactic acidosis, which has been observed in postmarketing cases. Clinicians should be aware of the reported outcomes, including death, hypothermia, hypotension, and resistant bradyarrhythmias, to ensure appropriate patient monitoring and management strategies. The presence of a Boxed Warning, the strongest warning that the FDA requires, underscores the importance of vigilance regarding this serious adverse event and its potential for severe clinical consequences.
Source
This label revision, introducing a Boxed Warning for Metformin Hydrochloride, was made effective by the FDA on 2026-06-25. Further details regarding the warning content are available on the DailyMed database, hosted by dailymed.nlm.nih.gov.